United Arab Emirates

Reimbursed Care Access

The United Arab Emirates maintains strict national controls on classic recreational psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, ibogaine, ayahuasca, 5‑MeO‑DMT), which are effectively prohibited outside of approved research. At the same time, pharmaceutical derivatives developed for medical use — notably esketamine (Spravato) — have been licensed/introduced into UAE clinical settings under Ministry of Health supervision, but access is typically limited to specialist clinics/private hospitals and reimbursement is uncommon or highly restricted. Ketamine is an approved anesthetic and is legally supplied for medical uses under prescription, but psychiatric (off‑label) ketamine infusion programs are generally delivered in private settings with limited public insurance reimbursement and variable prior‑authorization requirements.